NCT03643497 is a clinical trial of anti-infective drugs in Children；Infection, sponsored by Beijing Children's Hospital.

Who is sponsoring NCT03643497?

NCT03643497 is sponsored by Beijing Children's Hospital.

What drugs are being tested in NCT03643497?

Interventions in NCT03643497: anti-infective drugs.

What condition does NCT03643497 study?

NCT03643497 studies Children；Infection.

Is NCT03643497 still recruiting?

NCT03643497 is currently status unknown. Last updated 23 August 2018.

Last reviewed 2018-08-23 · How we verify

NCT03643497

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases

Status unknown Last updated 23 August 2018

What this trial tests

trial testing anti-infective drugs in Children；Infection in 800 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
30 September 2021

31 December 2021

Quick facts

Lead sponsor	Beijing Children's Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	800
Start date	1 July 2018
Primary completion	30 September 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

anti-infective drugs — full drug profile →

Conditions studied

Children；Infection — all drugs for Children；Infection →

Sponsor

Beijing Children's Hospital

Who can join

Adults 1 Day to 18, any sex, with Children；Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is based on the hypothesis that the pharmacokinetics of meropenem and linezolid in severe infectious children are different from mild infectious children and adults. The investigators aim to study the population pharmacokinetics of children receiving the meropenem and linezolid for treatment of severe infectious diseases. In this study, the investigators will detect drug concentration in plasma and cerebrospinal fluid by using residual blood samples of blood and cerebrospinal fluid gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models. In addition, the investigators also want to correlate use of meropenem and linezolid with treatment effectiveness and incidence of adverse effects in children. This novel knowledge will allow better and more rational approaches to the treatment of severe infectious diseases in children. It will also set the foundation for further studies to improve anti- infective drug therapies for severe infectious children.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.
Wang ZM, Chen XY, Bi J, Wang MY, et al · · 2020 · cited 21× · PMID 32513801 · DOI 10.1128/aac.00760-20
Improving the efficacy for meropenem therapy requires a high probability of target attainment in critically ill infants and children.
Wang Z, Bi J, You D, Tang Y, et al · · 2022 · cited 2× · PMID 36278190 · DOI 10.3389/fphar.2022.961863

Verify or expand the search:

Other Beijing Children's Hospital trials

Trials by the same sponsor.

NCT07412119 — Research on Disease Control and Mental Health Status of Adolescent Asthma Patients · not yet recruiting
NCT06837584 — Control and Treatment of Outpatient Children With Asthma · not yet recruiting
NCT07199101 — Multicenter Pediatric Low-Dose CT Protocol: Development and Clinical Verification · NA · not yet recruiting
NCT07488728 — Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-A · NA · recruiting
NCT07029958 — Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Vir · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03643497 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Children's Hospital
Last refreshed: 23 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03643497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing